



Contact:

Brendan Paul
The CHT Group
617-226-7184

REBIOTIX TO PRESENT AT 2014 BIO INTERNATIONAL CONVENTION

President and CEO to provide update on microbiota-suspension treatment for recurrent Clostridium difficile infection

San Diego, CA, June 3, 2014 – Rebiotix announced today that Lee Jones, founder, president and CEO will be presenting at the [2014 BIO International Convention](#). Hosted by the [Biotechnology Industry Organization](#) (BIO), this year’s global event for biotechnology will take place June 23-26 at the San Diego Convention Center in San Diego, California.

“I am excited to be presenting at this year’s BIO Convention regarding the progress we’ve made pioneering a new therapy to treat the life-threatening *Clostridium difficile* infection (*C. diff.*),” said Lee Jones, founder, president, CEO of Rebiotix. “Our company continues to get closer to making this therapy widely available to patients suffering from this debilitating condition.”

Rebiotix lead product, RBX2660 (microbiota suspension, targeted for the treatment of recurrent *C. diff.* represents the first drug product in the Rebiotix Microbiota Restoration Therapy platform. The US Food and Drug Administration recognized the urgent need for a new therapy for recurrent *C. diff.* and granted the RBX2660 clinical program Fast Track status.

C. diff. has become one of the most common health care-associated infections in the U.S., affecting more than 250,000 patients annually and linked to more than 14,000 deaths each year. Approximately, 20 to 30 percent of patients with *C. diff.* who are treated with antibiotics experience a recurrence. Currently, the only approved treatment for patients with recurrent *C. diff.* is more antibiotics, which can create a cycle of recurrence.

Rebiotix is currently working with the FDA to grant the next clinical trial phase towards commercialization.

###

ABOUT REBIOTIX

Rebiotix Inc. is a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases by harnessing the power of the human microbiome. The Roseville, Minn. based company is pioneering Microbiota Restoration Therapy to restore healthy gut flora through the transplantation of live microorganisms. For more information, visit www.rebiotix.com.

ABOUT THE BIO INTERNATIONAL CONVENTION

The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit convention.bio.org